The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-06. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Outside of the US, the drug thalidomide was marketed for the relief of general nausea and morning sickness, but caused birth defects and even the death of thousands of babies when taken during pregnancy. American mothers were largely unaffected as Frances Oldham Kelsey of the FDA refused to authorize the medication for market. In 1962, the Kefauver-Harris Amendment to the FD&C Act was passed, which represented a "revolution" in FDA regulatory authority. The most important change was the requirement that all new drug applications demonstrate "substantial evidence" of the drug's efficacy for a marketed indication, in addition to the existing requirement for pre-marketing demonstration of safety. This marked the start of the FDA approval process in its modern form. These reforms had the effect of increasing the time, and the difficulty, required to bring a drug to market. One of the most important statutes in establishing the modern American pharmaceutical market was the 1984 Drug Price Competition and Patent Term Restoration Act, more commonly known as the "Hatch-Waxman Act" after its chief sponsors. The act extended the patent exclusivity terms of new drugs, and tied those extensions, in part, to the length of the FDA approval process for each individual drug.
== Variants == When the total electron excitation energy of colliding particles is sufficient, then the bonding energy of two particles that bonded together can also be contributed into the associative penning ionization act. Associative Penning ionization can also occur:
=== Continuous and individualized delivery systems === As Parkinson's disease advances, the duration, efficacy and reliability of levodopa progressively decline producing unstable plasma concentration and motor fluctuations. The fluctuations contribute to a series of motor and non-motor complications including wearing off and levodopa induced dyskinesia that need a better tailored pharmaceutical approach to the disease. A steady activation of the dopaminergic receptors was initially pursued through intravenous infusion which shortly was replaced by a series of new levodopa device-aided formulations. Duodopa or Levodopa-carbidopa intestinal gel (LCIG) is a methylcellulose-based suspension of levodopa and carbidopa delivered in a continuous way into the duodenum or jejunum through a portable pump and a PEG-J tube system. In randomized studies, LCIG proved to reduce daily OFF time and increase ON time without troublesome dyskinesia but, at the same time, carries with it problems related to the infusion system, such as PEG-J and stoma complications. Produodopa is a soluble prodrug formulation of fosfolevodopa/foscarbidopa developed for a 24 hour subcutaneous infusion. After the infusion, the prodrug is converted by phosphatases into active levodopa and carbidopa that manage to stabilize their concentration in the blood. Compared with levodopa/carbidopa, the prodrug approach increases ON time without troublesome dyskinesia by 1.75 hours and reduced OFF time by 1.79 hours other than improvements also in quality of life, motor fluctuations and sleep.
The pancreas, located in the abdomen, below and behind the stomach, is both an exocrine and an endocrine gland. The alpha and beta cells are the endocrine cells in the pancreatic islets that release insulin and glucagon and smaller amounts of other hormones into the blood. Insulin and glucagon influence blood sugar levels. Glucagon is released when the blood glucose level is low and stimulates the liver to release glucose into the blood. Insulin increases the rate of glucose uptake and metabolism by most body cells. Somatostatin is released by delta cells and acts as an inhibitor of GH, insulin, and glucagon.
Sources: en.wikipedia.org
On Czapek Yeast Extract Agar medium at 25 °C, white colonies grow in a plane, attaining a velvety to deeply floccose texture, with colony sizes that are 33–35 mm in diameter. On this medium, olive conidia are produced. The reverse of the plate can be pale or slightly tinted brown. On Malt Extract Agar medium at 25 °C, growth is rare, yet rapid when occurring, forming a velvety surface. At first, colonies are yellow-green, but ultimately turn olive due to conidial production. Colony diameter can range in size from 35 mm to 70 mm. The reverse of the plate is similar to that observed for Czapek Yeast Extract Agar medium. On 25% Glycerol Nitrate Agar at 25 °C, colony growth is planar, yet develops into a thick gel, with colony size diameter ranging from 6–12 mm. The back of the plate is described as pale or olive. At 5 °C, 25% Glycerol Nitrate Agar supports germination and a colonial growth of up to 3 mm in diameter. This species fails to grow at 37 °C. On Creatine Sucrose Agar at 25 °C, colony size diameter ranges from 4 to 10 mm. Growth is restricted, and medium pH remains around 7. No change on the back of the plate is noted. Growth on media containing orange fruit pieces for seven days at room temperature results in fruit decay, accompanied by a characteristic odour. After 14 days at room temperature, the reverse is colourless to light brown.
The Great Zimbabwe Bird first appeared in an armorial sense when it was incorporated in the coat of arms of Southern Rhodesia, which were granted by Royal Warrant on 11 August 1924. It was first used on a national flag when the full arms were displayed on the Rhodesian flag that was adopted on 11 November 1968. It then appeared alone on the Zimbabwe Rhodesian flag of 1979, and it is now displayed on the flag of Zimbabwe. The arms of 1924 were initially retained by the Zimbabwean Government until a new coat of arms were adopted on 12 September 1981. The Zimbabwe Bird depicted on the flag is rendered in the same format as it appeared on the arms of 1924 and as it appeared on the Rhodesian flag of 1968 and the Zimbabwe Rhodesian flag of 1979. The red star on which the bird is placed is a regular star. However, a different, rather flattened version of the bird, sometimes displayed on an irregular, flattened star, is often seen on flags that are manufactured outside of Zimbabwe. The origin of this discrepancy appears to be an illustration of the proposed new flag that was first released by the Zimbabwe Ministry of Information in April 1980, just prior to the country attaining full independence. This illustration showed the bird in a flattened version positioned over an irregular star.
Thus, the formation of reactive oxygen species can be promoted. Moreover, arsenic could cause oxidative stress by depleting the cell's antioxidants, especially those containing thiol groups. The accumulation of reactive oxygen species like that cited above and hydroxyl radicals, superoxide radicals, and hydrogen peroxides causes aberrant gene expression at low concentrations and lesions of lipids, proteins, and DNA in higher concentrations, which eventually lead to cellular death. In a rat animal model, urine levels of 8-hydroxy-2'-deoxyguanosine (as a biomarker of DNA damage by reactive oxygen species) were measured after treatment with DMA(V). In comparison to control levels, they turned out to be significantly increased. This theory is further supported by a cross-sectional study which found elevated mean serum lipid peroxides in the As exposed individuals which correlated with blood levels of inorganic arsenic and methylated metabolites and inversely correlated with nonprotein sulfhydryl (NPSH) levels in whole blood. Another study found an association of As levels in whole blood with the level of reactive oxidants in plasma and an inverse relationship with plasma antioxidants. A finding of the latter study indicates that methylation might in fact be a detoxification pathway with regard to oxidative stress: the results showed that the lower the As methylation capacity was, the lower the level of plasma antioxidant capacity. As reviewed by Kitchin (2001), the oxidative stress theory explains the preferred tumor sites connected with arsenic exposure.
Sources: en.wikipedia.org
== External links == Major Lectins & Conjugated Lectins from different natural sources Functional Glycomics Gateway, a collaboration between the Consortium for Functional Glycomics and Nature Publishing Group Proteopedia shows more than 800 three-dimensional molecular models of lectins, fragments of lectins and complexes with carbohydrates EY Laboratories, Inc., Lectin and Lectin Conjugates manufacturer Recombinant Protein Purification Handbook Archived 2008-12-05 at the Wayback Machine Immobilized lectins, chromatography media Medicago AB, Lectin and Lectin Conjugates manufacturer Con A Proteopedia 1bxh, pokeweed lectin Proteopedia 1uha, Artocarpus lectin Proteopedia 1toq, Pterocarpus lectin Proteopedia 1q8v, Urtica lectin Proteopedia 1en2
=== Recent developments in non-invasive brain stimulation (TMS / tDCS) === During the past several years, both transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) have experienced significant evidence, regulatory analysis, and clinical implementation. According to a 2024 review by Desarkar et al., the body of research on the therapeutic application of non-invasive brain stimulation is growing and represents advancements in the quality of study, the parameters used in stimulation, and the mechanics of research, and the authors point to the progress of the research. The review also emphasizes limitations and ongoing challenges, including variability in individual response, the need for more standardized dosing protocols, and the importance of precise targeting based on neuroimaging or computational modeling. These findings update earlier assessments that characterized the evidence base as limited or inconsistent, particularly for tDCS, and reflect the increasing rigor of recent randomized and multi-site trials. Combination Therapies Emerging work has explored the joint use of multiple stimulation modalities. A 2024 clinical study by Zhou et al. reported that combined tDCS and repetitive TMS (rTMS) demonstrated promising benefits for insomnia, suggesting potential synergistic effects when protocols are integrated. The given combination is still under research, but it represents a broader tendency toward multimodal stimulation techniques.
=== Doping in sport === Phenylpiracetam has stimulant effects and may be used as a doping agent in sport. As a result, it is on the list of stimulants banned for in-competition use by the World Anti-Doping Agency (WADA). This list is applicable in all Olympic sports. Owing to its unique stimulant properties among racetams, phenylpiracetam is the only racetam on the WADA prohibited list.
Dislocations or subluxations (that is, partial dislocations) Sprains, tendinitis, or bursitis from activities. However, a 2018 study reports that while hypermobile individuals are more likely to suffer dislocations doing sports than non-hypermobile individuals, they are less likely to suffer muscle and tendon sprains. The overall chances of sports injury are not significantly different. Joint pain Back pain Joints that make clicking noises Chance of nerve compression disorders in the joints (such as carpal tunnel syndrome) "Growing pains" (as described in children in late afternoon or night)
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.